pharmaceuticals

pharmaceuticals Articles

Ionis Pharmaceuticals shares were relatively flat on Wednesday after the company announced a new collaboration with Roche to develop IONIS-FB-LRx for the treatment of complement-mediated diseases.
AcelRx shares made a solid gain on Wednesday despite a less-than-favorable update from the FDA. However, there is a vote for approval on Friday. and that seems to be what investors are optimistic...
The September 28 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks decreased.
Here 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the remainder of October.
Arrowhead Pharmaceuticals shares stumbled on Thursday after it announced a license and collaboration agreement with Janssen Pharmaceutica, a subsidiary of Johnson & Johnson.
Pfizer shares hit multiyear highs and nearly an all-time in Monday’s session after the pharma giant announced a succession plan for its CEO.
Here is a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the month of October.
The September 14 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
There is one fairly new effort for drug companies to mitigate the threat of generic drugs and for biotech companies to mitigate the threat of biosimilars. They can just launch their own. Several...
Acadia Pharmaceuticals shares popped after the company announced that the FDA completed a postmarketing review and issued a clear statement reaffirming the positive benefit-risk profile of Nuplazid...
AbbVie shares took a dip on Wednesday after it was announced that the pharma giant would be facing a lawsuit from the California Department of Insurance in regards to allegedy kickbacks given to...
Teva Pharmaceuticals shares made a solid gain on Monday morning after the company announced a critical approval by the FDA.
The August 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
With 2018 coming to a close in just a few months, Merrill Lynch is taking a close look at the biotech industry and what key catalysts to expect before 2019.
Here 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in September.